C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.
Lengyel
Ernst
E
Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Mail Code 2050, 5841 South Maryland Avenue, Chicago, IL 60637, USA. elengyel@uchicago.edu
Prechtel
Dieter
D
Resau
James H
JH
Gauger
Katja
K
Welk
Anita
A
Lindemann
Kristina
K
Salanti
Georgia
G
Richter
Thomas
T
Knudsen
Beatrice
B
Vande Woude
George F
GF
Harbeck
Nadia
N
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005348:Fibrocystic Breast Disease / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D017228:Hepatocyte Growth Factor / Q000378:metabolism; D006801:Humans; D006965:Hyperplasia / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D008024:Ligands; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis / Q000473:pathology*; D008875:Middle Aged; D009367:Neoplasm Staging; D010865:Pilot Projects; D019859:Proto-Oncogene Proteins c-met / Q000378:metabolism*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome
D017228:Hepatocyte Growth Factor; D008024:Ligands; D019859:Proto-Oncogene Proteins c-met; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone